drugset / Trial / NCT00466466
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not previously been treated with systemic chemotherapy.
Timeline
- Start
- 2007-04
- Primary completion
- 2010-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | — |
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |